Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Conditions
Interventions
Intervention1: INJ OCTREOTIDE: Injection Octreotide in dose of 100mcg subcutaneously 8 hourly till postoperative day 5
Control Intervention1: Injection normal saline(placebo): Injection normal saline
Sponsors
Sumit Bhaskar
Eligibility
Inclusion criteria
Inclusion criteria: Female patient age 25years or more with early breast carcinoma who underwent modified radical mastectomy giving consent for octreotide use
Exclusion criteria
Exclusion criteria: Patients with comorbidities like diabetes, thyroid disease, cardiac disease, pancreatitis, hepatic, renal impairment, previous irradiation to breast, hypersensitivity to octreotide, patient who received neoadjuvant therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| seroma formation Timepoint: 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| daily drain output in millilitersTimepoint: 24 hour postoperative till drain is removed;duration of seroma/lymphorrhea in daysTimepoint: 3 months;duration of hospital stay in daysTimepoint: 3 months;wound infectionTimepoint: 3 months;total no of lymph nodes dissectedTimepoint: 3 months;amount of seroma/lymphorrhea per lymph nodeTimepoint: 3 months;no. of positive lymph nodes resectedTimepoint: intra operatively;amount of seroma/lymphorrhea by positive lymph nodesTimepoint: 3 months;volume of seroma/lymphorrhea in millilitersTimepoint: 3 months | — |
Countries
India
Contacts
Public ContactSumit Bhaskar
GSVM medical college and LLR hospital
Outcome results
None listed